帕金森病标志物α-突触核蛋白聚集抑制剂的研究进展  

Research progress on inhibitors ofα-synuclein aggregation,a marker for Parkinson's disease

作　　者：李奇 秦亚娟[1] 唐立钧 LI Qi;QIN Yajuan;TANG Lijun(School of Pharmacy,Nanjing Medical University,Nanjing 211166;Department of Nuclear Medicine,the First Affiliated Hospital of Nanjing Medical University,Nanjing 210029,China)

机构地区：[1]南京医科大学药学院,江苏南京211166 [2]南京医科大学第一附属医院核医学科,江苏南京210029

出　　处：《南京医科大学学报(自然科学版)》2025年第3期404-417,共14页Journal of Nanjing Medical University(Natural Sciences)

基　　金：国家自然科学基金(82373728,82473768);江苏省自然科学基金(BK20231266)。

摘　　要：帕金森病(Parkinson’s disease,PD)是第二大神经退行性疾病,α-突触核蛋白(α-synuclein,α-syn)的病理性聚集体是PD的生物标志物,与PD的发生发展密切相关。寻找一种在疾病早期就能够抑制病理性聚集体如α-syn寡聚体与α-syn原纤维形成的抑制剂,对治疗PD具有重要意义。近年来以α-syn为靶点的聚集抑制剂研究有了显著进展。文章综述了α-syn的结构、生理功能、病理机制和聚集抑制剂的研究进展,旨在为α-syn聚集抑制剂进一步研发提供参考。Parkinson's disease(PD)is the second most common neurodegenerative disease.The pathological aggregation ofα-synuclein(α-syn)is a biomarker of PD,which is closely related to the occurrence and development of PD.Finding an inhibitor that can inhibit the formation of pathological aggregates such asα-syn oligomer andα-syn protofibrils at the early stage of the disease is of great significance for the treatment of PD.In recent years,significant progress has been made in the research of inhibitors targetingα-syn aggregation.This review summarizes the structure,physiological function,pathological mechanism and inhibitors ofα-syn aggregation,aiming to provide a reference for the further research and development ofα-syn aggregation inhibitors.

关 键 词：帕金森病 Α-突触核蛋白 聚集抑制剂 

分 类 号：R742.5[医药卫生—神经病学与精神病学]